AU2019232729B2 - Methods and compositions for treating cancer with ECM-affinity peptides linked to cytokines - Google Patents
Methods and compositions for treating cancer with ECM-affinity peptides linked to cytokines Download PDFInfo
- Publication number
- AU2019232729B2 AU2019232729B2 AU2019232729A AU2019232729A AU2019232729B2 AU 2019232729 B2 AU2019232729 B2 AU 2019232729B2 AU 2019232729 A AU2019232729 A AU 2019232729A AU 2019232729 A AU2019232729 A AU 2019232729A AU 2019232729 B2 AU2019232729 B2 AU 2019232729B2
- Authority
- AU
- Australia
- Prior art keywords
- leu
- ser
- val
- lys
- glu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4725—Proteoglycans, e.g. aggreccan
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2024259762A AU2024259762A1 (en) | 2018-03-05 | 2024-11-06 | Methods and compositions for treating cancer with ECM-affinity peptides linked to cytokines |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862638520P | 2018-03-05 | 2018-03-05 | |
| US62/638,520 | 2018-03-05 | ||
| US201862727156P | 2018-09-05 | 2018-09-05 | |
| US62/727,156 | 2018-09-05 | ||
| PCT/US2019/020685 WO2019173289A1 (en) | 2018-03-05 | 2019-03-05 | Methods and compositions for treating cancer with ecm-affinity peptides linked to cytokines |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2024259762A Division AU2024259762A1 (en) | 2018-03-05 | 2024-11-06 | Methods and compositions for treating cancer with ECM-affinity peptides linked to cytokines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019232729A1 AU2019232729A1 (en) | 2020-10-08 |
| AU2019232729B2 true AU2019232729B2 (en) | 2024-08-08 |
Family
ID=67847453
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019232729A Active AU2019232729B2 (en) | 2018-03-05 | 2019-03-05 | Methods and compositions for treating cancer with ECM-affinity peptides linked to cytokines |
| AU2024259762A Pending AU2024259762A1 (en) | 2018-03-05 | 2024-11-06 | Methods and compositions for treating cancer with ECM-affinity peptides linked to cytokines |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2024259762A Pending AU2024259762A1 (en) | 2018-03-05 | 2024-11-06 | Methods and compositions for treating cancer with ECM-affinity peptides linked to cytokines |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12365714B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3762407A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2021514661A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112292391A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2019232729B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020018196A2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019173289A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| SG11202100935TA (en) * | 2018-09-28 | 2021-02-25 | Massachusetts Inst Technology | Collagen-localized immunomodulatory molecules and methods thereof |
| EP3930687A4 (en) * | 2019-02-25 | 2023-06-07 | The University of Chicago | METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS |
| CN114206355A (zh) | 2019-06-03 | 2022-03-18 | 芝加哥大学 | 用靶向癌症的佐剂治疗癌症的方法和组合物 |
| WO2021174121A1 (en) * | 2020-02-27 | 2021-09-02 | Icahn School Of Medicine At Mount Sinai | Vegfr-3-activating agents and oncolytic viruses and uses thereof for the treatment of cancer |
| EP4262840A4 (en) * | 2020-12-18 | 2024-11-20 | Cullinan Amber Corp. | IMMUNOMODULATORY MOLECULES LOCALIZED IN BI-FUNCTIONAL LINEAR FUSION COLLAGEN AND THEIR METHODS |
| CN113350522B (zh) * | 2021-05-21 | 2022-08-30 | 浙江大学杭州国际科创中心 | 一种铂铜合金/氯离子转运体复合肿瘤治疗制剂及其制备方法、应用 |
| CN116999539A (zh) * | 2022-04-28 | 2023-11-07 | 天津大学 | 结直肠癌免疫治疗药物ifnbcol01 |
| EP4739334A1 (en) | 2023-07-05 | 2026-05-13 | Nanotein Technologies, Inc. | Cell signaling complexes and uses thereof |
| US12473529B2 (en) | 2023-07-18 | 2025-11-18 | Nanotein Technologies, Inc. | Reagents, reagent kits, and culture media for activating and expanding immune cells and uses thereof |
| WO2025245169A1 (en) * | 2024-05-21 | 2025-11-27 | Fred Hutchinson Cancer Center | Immunotherapy cells equipped with a collagen-targeting payload |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012112690A2 (en) * | 2011-02-16 | 2012-08-23 | Fabius Biotechnology | Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains |
| US20140315253A1 (en) * | 2005-12-26 | 2014-10-23 | Yantai Zhenghai Bio-Technology Co., Ltd. | Activated collagen scaffold materials and their special fused active restoration factors |
| WO2018195386A1 (en) * | 2017-04-20 | 2018-10-25 | The University Of Chicago | Methods and compositions for treating cancer with ecm-affinity peptides linked to immunotherapeutic antibodies |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2097032B (en) | 1981-04-22 | 1984-09-19 | Teron International Urban Dev | A combined ceiling air and services distribution system mechanical chasse and structural roof member |
| US4818542A (en) | 1983-11-14 | 1989-04-04 | The University Of Kentucky Research Foundation | Porous microspheres for drug delivery and methods for making same |
| US4879236A (en) | 1984-05-16 | 1989-11-07 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| US6130082A (en) | 1988-05-05 | 2000-10-10 | American Cyanamid Company | Recombinant flagellin vaccines |
| US5654270A (en) | 1988-06-28 | 1997-08-05 | La Jolla Cancer Research Foundation | Use of fibromodulin to prevent or reduce dermal scarring |
| US5962406A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
| DE4228457A1 (de) | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
| FR2722208B1 (fr) | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
| US5871986A (en) | 1994-09-23 | 1999-02-16 | The General Hospital Corporation | Use of a baculovirus to express and exogenous gene in a mammalian cell |
| US6103379A (en) | 1994-10-06 | 2000-08-15 | Bar-Ilan University | Process for the preparation of microspheres and microspheres made thereby |
| US6211159B1 (en) | 1997-04-11 | 2001-04-03 | University Of Toronto | Flagellin gene, FlaC of campylobacter |
| JP4375901B2 (ja) | 1997-11-28 | 2009-12-02 | 大日本住友製薬株式会社 | 新規な複素環化合物 |
| US6150022A (en) | 1998-12-07 | 2000-11-21 | Flex Products, Inc. | Bright metal flake based pigments |
| CA2378925C (en) | 1999-07-21 | 2010-04-06 | University Of Southern California | Matrix-targeted fusion polypeptides for tissue regeneration and wound healing |
| WO2001010912A1 (en) | 1999-08-09 | 2001-02-15 | Lexigen Pharmaceuticals Corp. | Multiple cytokine-antibody complexes |
| WO2001016180A2 (en) | 1999-08-27 | 2001-03-08 | Board Of Regents, The University Of Texas System | Cd40 agonist compositions and methods of use |
| US7192725B2 (en) | 2000-05-19 | 2007-03-20 | University Of Toronto | Flagellin gene, flaC of Campylobacter |
| KR100379250B1 (ko) | 2000-12-04 | 2003-04-08 | 한국과학기술연구원 | 나노 단위 크기의 금속 입자가 함유된 고분자 복합 소재및 그 제조 방법 |
| US20050037962A1 (en) | 2002-01-18 | 2005-02-17 | Ekker Stephen C. | Syndecans and angiogenesis |
| NZ535952A (en) | 2002-04-04 | 2009-01-31 | Coley Pharm Gmbh | Immunostimulatory G,U-containing oligoribonucleotides |
| AU2004271200A1 (en) * | 2003-09-05 | 2005-03-17 | Gtc Biotherapeutics, Inc. | Method for the production of fusion proteins in transgenic mammal milk |
| JP2007526253A (ja) | 2004-02-19 | 2007-09-13 | コーリー ファーマシューティカル グループ,インコーポレイテッド | 免疫刺激性ウイルスrnaオリゴヌクレオチド |
| WO2005082941A1 (en) | 2004-02-27 | 2005-09-09 | The University Of Western Ontario | Bone sialoprotein collagen-binding peptides |
| US8273357B2 (en) | 2004-07-16 | 2012-09-25 | Massachusetts Institute Of Technology | Antigen-carbohydrate conjugates |
| AU2006241149A1 (en) | 2005-04-26 | 2006-11-02 | Coley Pharmaceutical Gmbh | Modified oligoribonucleotide analogs with enhanced immunostimulatory activity |
| WO2007062107A2 (en) | 2005-11-25 | 2007-05-31 | Coley Pharmaceutical Gmbh | Immunostimulatory oligoribonucleotides |
| WO2008033432A2 (en) | 2006-09-12 | 2008-03-20 | Coley Pharmaceutical Group, Inc. | Immune modulation by chemically modified ribonucleosides and oligoribonucleotides |
| US20080160024A1 (en) | 2006-12-07 | 2008-07-03 | Board Of Trustees Of The University Of Arkansas | Inhibition of cancer metastasis |
| AT504685B1 (de) | 2006-12-20 | 2009-01-15 | Protaffin Biotechnologie Ag | Fusionsproteine |
| JP5639039B2 (ja) | 2008-04-11 | 2014-12-10 | メリマック ファーマシューティカルズ インコーポレーティッド | ヒト血清アルブミンリンカーおよびそのコンジュゲート |
| UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
| WO2010018132A1 (en) | 2008-08-11 | 2010-02-18 | Smithkline Beecham Corporation | Compounds |
| RU2579977C2 (ru) | 2009-11-13 | 2016-04-10 | Грифольс Терапьютикс Инк. | СОДЕРЖАЩИЕ ФАКТОР ФОН ВИЛЛЕБРАНДА (vWF) ПРЕПАРАТЫ И СПОСОБЫ, НАБОРЫ И ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ |
| US8734774B2 (en) | 2010-04-02 | 2014-05-27 | University Of Rochester | Protease activated cytokines |
| US9879062B2 (en) | 2012-07-03 | 2018-01-30 | Ecole Polytechnique Federale De Lausanne | Protein-binding peptide isolated from placenta growth factor |
| WO2015124297A1 (en) * | 2014-02-19 | 2015-08-27 | Merck Patent Gmbh | Cancer-targeted il-12 immunotherapy |
| US10420820B2 (en) | 2014-09-29 | 2019-09-24 | Counterpoint Biomedia LLC | Targeting of pharmaceutical agents to pathologic areas using bifunctional fusion polypeptides |
| CN107073132B (zh) | 2014-10-06 | 2021-08-27 | 梅约医学教育与研究基金会 | 载体-抗体组合物及其制备和使用方法 |
| US20200331984A1 (en) * | 2016-09-20 | 2020-10-22 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Harnessing protein-based drugs comprising an anchor domain for use on the ocular surface |
| WO2018184003A1 (en) | 2017-03-31 | 2018-10-04 | Dana-Farber Cancer Institute, Inc. | Modulating dsrna editing, sensing, and metabolism to increase tumor immunity and improve the efficacy of cancer immunotherapy and/or modulators of intratumoral interferon |
| WO2019222296A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
| WO2020041758A1 (en) | 2018-08-24 | 2020-02-27 | City Of Hope | Masked cytokine conjugates |
| EP3930687A4 (en) * | 2019-02-25 | 2023-06-07 | The University of Chicago | METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS |
-
2019
- 2019-03-05 CN CN201980030391.2A patent/CN112292391A/zh active Pending
- 2019-03-05 BR BR112020018196-0A patent/BR112020018196A2/pt unknown
- 2019-03-05 WO PCT/US2019/020685 patent/WO2019173289A1/en not_active Ceased
- 2019-03-05 US US15/733,582 patent/US12365714B2/en active Active
- 2019-03-05 AU AU2019232729A patent/AU2019232729B2/en active Active
- 2019-03-05 JP JP2020546407A patent/JP2021514661A/ja active Pending
- 2019-03-05 EP EP19764476.8A patent/EP3762407A4/en active Pending
-
2024
- 2024-03-08 JP JP2024035825A patent/JP2024069367A/ja active Pending
- 2024-11-06 AU AU2024259762A patent/AU2024259762A1/en active Pending
-
2025
- 2025-06-25 US US19/249,789 patent/US20260049115A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140315253A1 (en) * | 2005-12-26 | 2014-10-23 | Yantai Zhenghai Bio-Technology Co., Ltd. | Activated collagen scaffold materials and their special fused active restoration factors |
| WO2012112690A2 (en) * | 2011-02-16 | 2012-08-23 | Fabius Biotechnology | Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains |
| WO2018195386A1 (en) * | 2017-04-20 | 2018-10-25 | The University Of Chicago | Methods and compositions for treating cancer with ecm-affinity peptides linked to immunotherapeutic antibodies |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019232729A1 (en) | 2020-10-08 |
| AU2024259762A1 (en) | 2024-11-28 |
| CN112292391A (zh) | 2021-01-29 |
| US20260049115A1 (en) | 2026-02-19 |
| JP2024069367A (ja) | 2024-05-21 |
| EP3762407A4 (en) | 2021-11-24 |
| US12365714B2 (en) | 2025-07-22 |
| EP3762407A1 (en) | 2021-01-13 |
| JP2021514661A (ja) | 2021-06-17 |
| US20210094995A1 (en) | 2021-04-01 |
| BR112020018196A2 (pt) | 2020-12-29 |
| WO2019173289A1 (en) | 2019-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260049115A1 (en) | Methods and compositions for treating cancer with ecm-affinity peptides linked to cytokines | |
| US20230377764A1 (en) | Methods and compositions for treating cancer with ecm-affinity peptides linked to immunotherapeutic antibodies | |
| US20220241370A1 (en) | Compositions and methods for subcutaneous administration of cancer immunotherapy | |
| IL183710A (en) | Conjugated product | |
| JP7611136B2 (ja) | 別の薬理学的に活性な薬剤と組み合わせた長時間作用型インターロイキン-15受容体作動薬 | |
| JP2025089477A (ja) | 細胞免疫療法を増強するための方法 | |
| JP7680375B2 (ja) | コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物 | |
| JP2024517871A (ja) | プロテアーゼ活性化治療剤を含む組成物および方法 | |
| US20210106652A1 (en) | Immunogenic Compounds For Treatment Of Fibrosis, Autoimmune Diseases And Inflammation | |
| JP2020501513A (ja) | 治療用多標的コンストラクトおよびその使用 | |
| WO2008152508A2 (en) | Cytokine conjugate | |
| US9561289B2 (en) | Peptides for inhibiting tumor growth | |
| BR122026001844A2 (pt) | Polipeptídeo compreendendo um peptídeo de afinidade com ecm ligado a citocina, vetor de ácido nucleico e composição compreendendo o dito polipeptídeo, bem como método para preparar o mesmo e uso do mesmo ou da composição para tratar câncer | |
| EP4727961A2 (en) | Methods and compositions comprising engineered il-7 and il-12 polypeptides for treating cancer | |
| CN117777303A (zh) | 一种高亲和力pd1蛋白偶联物及其应用 | |
| WO2026003203A1 (en) | Combination of an immunocytokine comprising targeted il2 and a jak inhibitor | |
| EA046466B1 (ru) | Длительно действующий агонист рецептора интерлейкина-15 в комбинации с другим фармакологически активным средством |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |